# Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control

> **NCT07458880** · NA · RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 140 (estimated)

## Conditions studied

- Intracerebral Hemorrhage

## Interventions

- **DRUG:** Exforge HCT® or Three Individual drug amlodipine + valsartan + hydrochlorothiazide

## Key facts

- **NCT ID:** NCT07458880
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2029-09-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07458880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07458880, "Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT07458880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*